Concepts (97)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 8 | 2024 | 53 | 1.340 |
Why?
|
| Graft Survival | 5 | 2024 | 40 | 0.410 |
Why?
|
| Living Donors | 3 | 2024 | 20 | 0.380 |
Why?
|
| Retrospective Studies | 8 | 2024 | 767 | 0.280 |
Why?
|
| Child, Preschool | 8 | 2024 | 1675 | 0.280 |
Why?
|
| Male | 14 | 2024 | 6489 | 0.270 |
Why?
|
| Postoperative Complications | 3 | 2024 | 32 | 0.270 |
Why?
|
| Child | 8 | 2024 | 2180 | 0.250 |
Why?
|
| Female | 15 | 2024 | 8751 | 0.250 |
Why?
|
| Renal Dialysis | 2 | 2015 | 25 | 0.240 |
Why?
|
| Kidney Failure, Chronic | 2 | 2015 | 25 | 0.240 |
Why?
|
| Blood Group Incompatibility | 1 | 2024 | 3 | 0.230 |
Why?
|
| ABO Blood-Group System | 1 | 2024 | 5 | 0.230 |
Why?
|
| Waiting Lists | 1 | 2024 | 8 | 0.230 |
Why?
|
| Tissue and Organ Procurement | 2 | 2024 | 14 | 0.230 |
Why?
|
| Biliary Atresia | 2 | 2024 | 6 | 0.230 |
Why?
|
| South Africa | 13 | 2024 | 7312 | 0.230 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2023 | 25 | 0.220 |
Why?
|
| Pharmacogenetics | 1 | 2023 | 27 | 0.220 |
Why?
|
| Kidney Transplantation | 2 | 2020 | 42 | 0.220 |
Why?
|
| Infant | 7 | 2024 | 2145 | 0.210 |
Why?
|
| Humans | 16 | 2024 | 14077 | 0.210 |
Why?
|
| Adolescent | 7 | 2024 | 2858 | 0.210 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2020 | 103 | 0.200 |
Why?
|
| Liver Failure, Acute | 1 | 2020 | 3 | 0.180 |
Why?
|
| Nephrotic Syndrome | 1 | 2019 | 5 | 0.170 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2019 | 5 | 0.170 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2019 | 5 | 0.170 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 14 | 0.170 |
Why?
|
| Amino Acid Substitution | 1 | 2019 | 35 | 0.170 |
Why?
|
| Hepatectomy | 1 | 2019 | 2 | 0.170 |
Why?
|
| Quality Improvement | 1 | 2020 | 32 | 0.170 |
Why?
|
| Membrane Proteins | 1 | 2019 | 34 | 0.170 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 47 | 0.170 |
Why?
|
| Comorbidity | 1 | 2020 | 184 | 0.160 |
Why?
|
| Alleles | 1 | 2019 | 134 | 0.160 |
Why?
|
| Liver Failure | 1 | 2018 | 5 | 0.160 |
Why?
|
| Sepsis | 1 | 2020 | 101 | 0.160 |
Why?
|
| Chemoprevention | 1 | 2018 | 33 | 0.160 |
Why?
|
| Mutation | 1 | 2019 | 299 | 0.150 |
Why?
|
| Middle Aged | 6 | 2024 | 3425 | 0.130 |
Why?
|
| Adult | 7 | 2024 | 5664 | 0.130 |
Why?
|
| Survival Rate | 3 | 2024 | 96 | 0.130 |
Why?
|
| Peritoneal Dialysis | 1 | 2015 | 8 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 48 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 68 | 0.120 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 163 | 0.110 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 367 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 247 | 0.100 |
Why?
|
| HIV Seropositivity | 1 | 2015 | 263 | 0.100 |
Why?
|
| Young Adult | 3 | 2024 | 2357 | 0.100 |
Why?
|
| Infant, Newborn | 3 | 2020 | 1410 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2019 | 867 | 0.090 |
Why?
|
| End Stage Liver Disease | 1 | 2024 | 5 | 0.060 |
Why?
|
| Graft Rejection | 1 | 2024 | 14 | 0.060 |
Why?
|
| Metabolic Clearance Rate | 1 | 2023 | 11 | 0.060 |
Why?
|
| Drug Discovery | 1 | 2023 | 22 | 0.060 |
Why?
|
| Risk Factors | 2 | 2020 | 1431 | 0.050 |
Why?
|
| Liver | 1 | 2023 | 74 | 0.050 |
Why?
|
| Aged | 2 | 2020 | 1650 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2002 | 5 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2002 | 20 | 0.050 |
Why?
|
| Genomics | 1 | 2022 | 106 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2022 | 100 | 0.050 |
Why?
|
| Insulin Resistance | 1 | 2002 | 79 | 0.050 |
Why?
|
| HIV Infections | 1 | 2018 | 4946 | 0.040 |
Why?
|
| Sampling Studies | 1 | 2020 | 13 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2002 | 137 | 0.040 |
Why?
|
| Steroids | 1 | 2019 | 14 | 0.040 |
Why?
|
| Apolipoprotein L1 | 1 | 2019 | 6 | 0.040 |
Why?
|
| Pedigree | 1 | 2019 | 30 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2019 | 35 | 0.040 |
Why?
|
| Operative Time | 1 | 2019 | 4 | 0.040 |
Why?
|
| Length of Stay | 1 | 2019 | 43 | 0.040 |
Why?
|
| Patient Selection | 1 | 2019 | 40 | 0.040 |
Why?
|
| Haplotypes | 1 | 2019 | 119 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 409 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 449 | 0.040 |
Why?
|
| Time Factors | 2 | 2015 | 503 | 0.040 |
Why?
|
| Genotype | 1 | 2019 | 430 | 0.040 |
Why?
|
| DNA, Viral | 1 | 2018 | 165 | 0.040 |
Why?
|
| Incidence | 1 | 2020 | 655 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2018 | 303 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2020 | 939 | 0.040 |
Why?
|
| Developing Countries | 1 | 2020 | 385 | 0.040 |
Why?
|
| HIV Antibodies | 1 | 2018 | 243 | 0.030 |
Why?
|
| HIV | 1 | 2018 | 380 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2015 | 89 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 37 | 0.030 |
Why?
|
| Viral Load | 1 | 2018 | 808 | 0.030 |
Why?
|
| Homeostasis | 1 | 2002 | 9 | 0.010 |
Why?
|
| C-Peptide | 1 | 2002 | 13 | 0.010 |
Why?
|
| Glycated Hemoglobin A | 1 | 2002 | 24 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2002 | 131 | 0.010 |
Why?
|
| Models, Biological | 1 | 2002 | 77 | 0.010 |
Why?
|
| Insulin | 1 | 2002 | 72 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2002 | 106 | 0.010 |
Why?
|